
β3-Adrenoceptor agonists like mirabegron and vibegron improve overactive bladder (OAB) symptoms beyond detrusor relaxation. The review highlights their potential roles in reducing fibrosis, hypertrophy, and apoptosis, while prolonged use may desensitize relaxation responses. Limited data suggest structural bladder changes contribute to clinical benefits seen after 4 weeks. Further long-term studies are needed to confirm these mechanisms and optimize OAB treatment.
Like
Save
Share